Leerink sets $36 price target for Latigo Biotherapeutics
Latigo Biotherapeutics was initiated at an Outperform rating by Leerink Partners, with a $36.00/share price target announced, per TradingView News.
Ratings actions GMT) Latigo Biotherapeutics Initiated at Outperform by Leerink PartnersRatings actions